首页> 外文期刊>Behavioural Brain Research: An International Journal >Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model
【24h】

Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model

机译:(r)-ketamine的有益效果,但不是其代谢物(2r,6r) - 羟基炔胺,在慢性社会失败压力模型中抑郁状表型,炎性骨标志物和骨矿物密度

获取原文
获取原文并翻译 | 示例
       

摘要

Inflammatory bone markers may play a role in the antidepressant actions of (R)-ketamine in susceptible mice after chronic social defeat stress (CSDS). In this study, we compared the effects of (R)-ketamine and its final metabolite (2R,6R)-hydroxynorketamine (HNK) in depression-like phenotypes, inflammatory bone markers and bone mineral density (BMD) in CSDS susceptible mice. We measured plasma levels of inflammatory bone markers, which included osteoprotegerin (OPG), receptor activator of nuclear factor KB ligand (RANKL), and osteopontin after behavioral tests. (R)-ketamine, but not (2R,6R)-HNK, elicited rapid and sustained anti-depressant effects in CSDS susceptible mice. Furthermore, (R)-ketamine, but not (2R,6R)-HNK, significantly improved the increased plasma levels of RANKL and decreased OPG/RANKL ratio in CSDS susceptible mice. Moreover, (R)-ketamine, but not (2R,6R)-HNK, significantly attenuated the decreased BMD in CSDS susceptible mice. These findings demonstrate that (R)-ketamine may have beneficial effects in depression-like phenotype and abnormalities in bone functions of CSDS susceptible mice. It is, therefore, likely that (R)-ketamine would be a potential therapeutic drug for abnormalities in bone metabolism in depressed patients.
机译:炎症性骨标志物可能在慢性社会失败压力(CSDS)之后在易感小鼠中的(R)-Ketamine的抗抑郁作用中发挥作用。在这项研究中,我们将(R)-Ketamine及其最终代谢物(2R,6R) - 羟基炔胺(HNK)的抑制表型表型,炎性骨标志物和骨矿物密度(BMD)的影响进行了比较了CSDS易感小鼠的效果。我们测量炎症骨标志物的血浆水平,其中包括骨蛋白酶(OPG),核因子Kb配体(RANKL)的受体激活剂,以及行为试验后的骨桥蛋白。 (r)-Ketamine,但不是(2R,6R)-HNK,引发CSDS易感小鼠中的快速和持续的抗抑制作用。此外,(R)-Ketamine,但不是(2R,6R)-HNK,显着改善了CSDS易感小鼠中的RANKL的增加和降低的OPG / RANKL比率。此外,(R)-Ketamine,但不是(2R,6R)-HNK,显着减弱了CSDS易感小鼠中的降低的BMD。这些发现表明(R)-Ketamine可能对CSDS易感小鼠的骨功能的抑郁状表型和异常具有有益的作用。因此,(R)-Ketamine可能是抑郁症患者骨代谢异常的潜在治疗药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号